Publications | PubMed=7175440; DOI=10.1084/jem.156.6.1755 Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J. Exp. Med. 156:1755-1766(1982) PubMed=7747814 Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H., Cordon-Cardo C., Kamb A. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am. J. Pathol. 146:1199-1206(1995) PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 22:157-163(1998) PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311 Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M., Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T., Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L., Sharpless N.E. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Res. 67:1502-1512(2007) PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958 Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res. 71:2561-2571(2011) PubMed=21725359; DOI=10.1038/onc.2011.250 Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M., She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I., Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G., Wolchok J.D., Houghton A.N., Solit D.B. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 31:446-457(2012) PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625 Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L., Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A., Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F., Rosen N., Solit D.B. Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res. 74:2340-2350(2014) PubMed=25645078; DOI=10.1186/s12943-015-0293-5 Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A., Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B., Graeber T.G., Ribas A. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol. Cancer 14:27.1-27.12(2015) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005 Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) |